Saroja Ramanujan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Saroja Ramanujan has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Kapil Gadkar
Genentech, Inc. South San Francisco California USA
8 shared publicationsIraj Hosseini
Genentech Inc., South San Francisco, USA
3 shared publicationsK Gadkar
Preclinical and Translational Pharmacokinetics Department, Genentech, South San Francisco, California, USA
3 shared publicationsChristine Orr
Genentech Research & Early Development, 1 DNA Way, South San Francisco, CA 94080 USA
2 shared publicationsDaniel C. Kirouac
Genentech Research & Early Development, 1 DNA Way, South San Francisco, CA 94080 USA
2 shared publicationsGabriele Schaefer
Genentech Research & Early Development, 1 DNA Way, South San Francisco, CA 94080 USA
2 shared publications
Latest Publications
- Open Access
Leveraging protein language and structural models for early prediction of antibodies with fast clearance
Monoclonal antibodies (mAbs) with long systemic persistence are widely used as therapeutics. However, antibodies with atypically fast clearance require more dosing, limiting their clinical usefulness. Deep learning can facilitate using sequence-based modeling to predict potential pharmacokinetic (PK) liabilities before antibody generation. Assembling a dataset of 103 mAbs with measured nonspecific clearance in cynomolgus monkeys (cyno), and using transfer learning from large protein language models, we developed multiple machine learning models to predict mAb clearance as fast/slow clearing. Focusing on minimizing misclassification of potentially promising molecules as fast clearing, our results show that using physicochemical properties yielded up to 73.1+/-1.1% classification accuracy on hold-out test data (precision 65.2+/-2.3%). Using only sequence-based features from deep learning protein language models yielded a comparable performance of 71+/-1.4% (precision 65.5+/-2.5%). Combining structural and deep learning derived features yielded a similar accuracy of 73.9+/-1.1%, and slightly improved precision (68.3+/-2.4%). Features important for classifying fast/slow clearance point to charge, moment, and surface area properties at pH 7.4 as well as deep learning derived features. These results suggest that the protein language models provide comparable information and predictive performance of clearance as physicochemical features. This work provides a foundation for in silico prediction of protein pharmacokinetics to inform antibody candidate generation and early deprioritization of designs with high risk of fast clearance. More generally, it illustrates the value of transfer learning-based application of protein language models to address characteristics of importance for protein therapeutics.
Open AccessLeveraging protein language and structural models for early prediction of antibodies with fast clearance
Monoclonal antibodies (mAbs) with long systemic persistence are widely used as therapeutics. However, antibodies with atypically fast clearance require more dosing, limiting their clinical usefulness. Deep learning can facilitate using sequence-based modeling to predict potential pharmacokinetic (PK) liabilities before antibody generation. Assembling a dataset of 103 mAbs with measured nonspecific clearance in cynomolgus monkeys (cyno), and using transfer learning from large protein language models, we developed multiple machine learning models to predict mAb clearance as fast/slow clearing. Focusing on minimizing misclassification of potentially promising molecules as fast clearing, our results show that using physicochemical properties yielded up to 73.1+/-1.1% classification accuracy on hold-out test data (precision 65.2+/-2.3%). Using only sequence-based features from deep learning protein language models yielded a comparable performance of 71+/-1.4% (precision 65.5+/-2.5%). Combining structural and deep learning derived features yielded a similar accuracy of 73.9+/-1.1%, and slightly improved precision (68.3+/-2.4%). Features important for classifying fast/slow clearance point to charge, moment, and surface area properties at pH 7.4 as well as deep learning derived features. These results suggest that the protein language models provide comparable information and predictive performance of clearance as physicochemical features. This work provides a foundation for in silico prediction of protein pharmacokinetics to inform antibody candidate generation and early deprioritization of designs with high risk of fast clearance. More generally, it illustrates the value of transfer learning-based application of protein language models to address characteristics of importance for protein therapeutics.
- Open Access
- 16 May 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (3) , 531-545
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper
The landscape of oncology drug development has witnessed remarkable advancements over the last few decades, significantly improving clinical outcomes and quality of life for patients with cancer. Project Optimus, introduced by the U.S. Food and Drug Administration, stands as a groundbreaking endeavor to reform dose selection of oncology drugs, presenting both opportunities and challenges for the field. To address complex dose optimization challenges, an Oncology Dose Optimization IQ Working Group was created to characterize current practices, provide recommendations for improvement, develop a clinical toolkit, and engage Health Authorities. Historically, dose selection for cytotoxic chemotherapeutics has focused on the maximum tolerated dose, a paradigm that is less relevant for targeted therapies and new treatment modalities. A survey conducted by this group gathered insights from member companies regarding industry practices in oncology dose optimization. Given oncology drug development is a complex effort with multidimensional optimization and high failure rates due to lack of clinically relevant efficacy, this Working Group advocates for a case‐by‐case approach to inform the timing, specific quantitative targets, and strategies for dose optimization, depending on factors such as disease characteristics, patient population, mechanism of action, including associated resistance mechanisms, and therapeutic index. This white paper highlights the evolving nature of oncology dose optimization, the impact of Project Optimus, and the need for a tailored and evidence‐based approach to optimize oncology drug dosing regimens effectively.
- 16 May 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (3) , 531-545
Open AccessDose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper
The landscape of oncology drug development has witnessed remarkable advancements over the last few decades, significantly improving clinical outcomes and quality of life for patients with cancer. Project Optimus, introduced by the U.S. Food and Drug Administration, stands as a groundbreaking endeavor to reform dose selection of oncology drugs, presenting both opportunities and challenges for the field. To address complex dose optimization challenges, an Oncology Dose Optimization IQ Working Group was created to characterize current practices, provide recommendations for improvement, develop a clinical toolkit, and engage Health Authorities. Historically, dose selection for cytotoxic chemotherapeutics has focused on the maximum tolerated dose, a paradigm that is less relevant for targeted therapies and new treatment modalities. A survey conducted by this group gathered insights from member companies regarding industry practices in oncology dose optimization. Given oncology drug development is a complex effort with multidimensional optimization and high failure rates due to lack of clinically relevant efficacy, this Working Group advocates for a case‐by‐case approach to inform the timing, specific quantitative targets, and strategies for dose optimization, depending on factors such as disease characteristics, patient population, mechanism of action, including associated resistance mechanisms, and therapeutic index. This white paper highlights the evolving nature of oncology dose optimization, the impact of Project Optimus, and the need for a tailored and evidence‐based approach to optimize oncology drug dosing regimens effectively.
- Open Access
- 15 May 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (5) , 660
A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule
FLT3L-Fc is a half-life extended, effectorless Fc-fusion of the native human FLT3-ligand. In cynomolgus monkeys, treatment with FLT3L-Fc leads to a complex pharmacokinetic/pharmacodynamic (PK/PD) relationship, with observed nonlinear PK and expansion of different immune cell types across different dose levels. A minimal physiologically based PK/PD model with expansion-enhanced target-mediated drug disposition (TMDD) was developed to integrate the molecule’s mechanism of action, as well as the complex preclinical and clinical PK/PD data, to support the preclinical-to-clinical translation of FLT3L-Fc. In addition to the preclinical PK data of FLT3L-Fc in cynomolgus monkeys, clinical PK and PD data from other FLT3-agonist molecules (GS-3583 and CDX-301) were used to inform the model and project the expansion profiles of conventional DC1s (cDC1s) and total DCs in peripheral blood. This work constitutes an essential part of our model-informed drug development (MIDD) strategy for clinical development of FLT3L-Fc by projecting PK/PD in healthy volunteers, determining the first-in-human (FIH) dose, and informing the efficacious dose in clinical settings. Model-generated results were incorporated in regulatory filings to support the rationale for the FIH dose selection.
- 15 May 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (5) , 660
Open AccessA Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule
FLT3L-Fc is a half-life extended, effectorless Fc-fusion of the native human FLT3-ligand. In cynomolgus monkeys, treatment with FLT3L-Fc leads to a complex pharmacokinetic/pharmacodynamic (PK/PD) relationship, with observed nonlinear PK and expansion of different immune cell types across different dose levels. A minimal physiologically based PK/PD model with expansion-enhanced target-mediated drug disposition (TMDD) was developed to integrate the molecule’s mechanism of action, as well as the complex preclinical and clinical PK/PD data, to support the preclinical-to-clinical translation of FLT3L-Fc. In addition to the preclinical PK data of FLT3L-Fc in cynomolgus monkeys, clinical PK and PD data from other FLT3-agonist molecules (GS-3583 and CDX-301) were used to inform the model and project the expansion profiles of conventional DC1s (cDC1s) and total DCs in peripheral blood. This work constitutes an essential part of our model-informed drug development (MIDD) strategy for clinical development of FLT3L-Fc by projecting PK/PD in healthy volunteers, determining the first-in-human (FIH) dose, and informing the efficacious dose in clinical settings. Model-generated results were incorporated in regulatory filings to support the rationale for the FIH dose selection.
- Open Access
- 26 January 2024
- Published by Springer Nature in npj Systems Biology and Applications
- Vol. 10 (1) , 1-12
Digital twins elucidate critical role of Tscm in clinical persistence of TCR-engineered cell therapy
Despite recent progress in adoptive T cell therapy for cancer, understanding and predicting the kinetics of infused T cells remains a challenge. Multiple factors can impact the distribution, expansion, and decay or persistence of infused T cells in patients. We have developed a novel quantitative systems pharmacology (QSP) model of TCR-transgenic T cell therapy in patients with solid tumors to describe the kinetics of endogenous T cells and multiple memory subsets of engineered T cells after infusion. These T cells undergo lymphodepletion, proliferation, trafficking, differentiation, and apoptosis in blood, lymph nodes, tumor site, and other peripheral tissues. Using the model, we generated patient-matched digital twins that recapitulate the circulating T cell kinetics reported from a clinical trial of TCR-engineered T cells targeting E7 in patients with metastatic HPV-associated epithelial cancers. Analyses of key parameters influencing cell kinetics and differences among digital twins identify stem cell-like memory T cells (Tscm) cells as an important determinant of both expansion and persistence and suggest that Tscm-related differences contribute significantly to the observed variability in cellular kinetics among patients. We simulated in silico clinical trials using digital twins and predict that Tscm enrichment in the infused product improves persistence of the engineered T cells and could enable administration of a lower dose. Finally, we verified the broader relevance of the QSP model, the digital twins, and findings on the importance of Tscm enrichment by predicting kinetics for two patients with pancreatic cancer treated with KRAS G12D targeting T cell therapy. This work offers insight into the key role of Tscm biology on T cell kinetics and provides a quantitative framework to evaluate cellular kinetics for future efforts in the development and clinical application of TCR-engineered T cell therapies.
- 26 January 2024
- Published by Springer Nature in npj Systems Biology and Applications
- Vol. 10 (1) , 1-12
Open AccessDigital twins elucidate critical role of Tscm in clinical persistence of TCR-engineered cell therapy
Despite recent progress in adoptive T cell therapy for cancer, understanding and predicting the kinetics of infused T cells remains a challenge. Multiple factors can impact the distribution, expansion, and decay or persistence of infused T cells in patients. We have developed a novel quantitative systems pharmacology (QSP) model of TCR-transgenic T cell therapy in patients with solid tumors to describe the kinetics of endogenous T cells and multiple memory subsets of engineered T cells after infusion. These T cells undergo lymphodepletion, proliferation, trafficking, differentiation, and apoptosis in blood, lymph nodes, tumor site, and other peripheral tissues. Using the model, we generated patient-matched digital twins that recapitulate the circulating T cell kinetics reported from a clinical trial of TCR-engineered T cells targeting E7 in patients with metastatic HPV-associated epithelial cancers. Analyses of key parameters influencing cell kinetics and differences among digital twins identify stem cell-like memory T cells (Tscm) cells as an important determinant of both expansion and persistence and suggest that Tscm-related differences contribute significantly to the observed variability in cellular kinetics among patients. We simulated in silico clinical trials using digital twins and predict that Tscm enrichment in the infused product improves persistence of the engineered T cells and could enable administration of a lower dose. Finally, we verified the broader relevance of the QSP model, the digital twins, and findings on the importance of Tscm enrichment by predicting kinetics for two patients with pancreatic cancer treated with KRAS G12D targeting T cell therapy. This work offers insight into the key role of Tscm biology on T cell kinetics and provides a quantitative framework to evaluate cellular kinetics for future efforts in the development and clinical application of TCR-engineered T cell therapies.
- Open Access
- 20 April 2023
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 186, 106450
Complex PK-PD of an engineered IL-15/IL-15Rα–Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics
- 20 April 2023
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 186, 106450
Open AccessComplex PK-PD of an engineered IL-15/IL-15Rα–Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics
- Open Access
- 20 July 2022
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 11 (9) , 1268-1277
Integrated systems modeling of severe asthma: Exploration of IL‐33/ST2 antagonism
Asthma is a complex, heterogeneous disease with a high unmet medical need, despite therapies targeting a multitude of pathways. The ability to quantitatively integrate preclinical and clinical data on these pathways could aid in the development and testing of novel targets and therapeutics. In this work, we develop a computational model of asthma biology, including key cell types and mediators, and create a virtual population capturing clinical heterogeneity. The simulated responses to therapies targeting IL-13, IL-4R alpha, IL-5, IgE, and TSLP demonstrate agreement with clinical endpoints and biomarkers of type 2 (T2) inflammation, including blood eosinophils, FEV1, IgE, and FeNO. We use the model to explore the potential benefit of targeting the IL-33 pathway with anti-IL-33 and anti-ST2. Model predictions are compared with data on blood eosinophils, FeNO, and FEV1 from recent anti-IL-33 and anti-ST2 trials and used to interpret trial results based on pathway biology and pharmacology. Results of sensitivity analyses on the contributions of IL-33 to the predicted biomarker changes suggest that anti-ST2 therapy reduces circulating blood eosinophil levels primarily through its impact on eosinophil progenitor maturation and IL-5-dependent survival, and induces changes in FeNO and FEV1 through its effect on immune cells involved in T2 cytokine production. Finally, we also investigate the impact of ST2 genetics on the conferred benefit of anti-ST2. The model includes representation of a wide array of biologic mechanisms and interventions that will provide mechanistic insight and support clinical program design for a wide range of novel therapies during drug development.
- 20 July 2022
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 11 (9) , 1268-1277
Open AccessIntegrated systems modeling of severe asthma: Exploration of IL‐33/ST2 antagonism
Asthma is a complex, heterogeneous disease with a high unmet medical need, despite therapies targeting a multitude of pathways. The ability to quantitatively integrate preclinical and clinical data on these pathways could aid in the development and testing of novel targets and therapeutics. In this work, we develop a computational model of asthma biology, including key cell types and mediators, and create a virtual population capturing clinical heterogeneity. The simulated responses to therapies targeting IL-13, IL-4R alpha, IL-5, IgE, and TSLP demonstrate agreement with clinical endpoints and biomarkers of type 2 (T2) inflammation, including blood eosinophils, FEV1, IgE, and FeNO. We use the model to explore the potential benefit of targeting the IL-33 pathway with anti-IL-33 and anti-ST2. Model predictions are compared with data on blood eosinophils, FeNO, and FEV1 from recent anti-IL-33 and anti-ST2 trials and used to interpret trial results based on pathway biology and pharmacology. Results of sensitivity analyses on the contributions of IL-33 to the predicted biomarker changes suggest that anti-ST2 therapy reduces circulating blood eosinophil levels primarily through its impact on eosinophil progenitor maturation and IL-5-dependent survival, and induces changes in FeNO and FEV1 through its effect on immune cells involved in T2 cytokine production. Finally, we also investigate the impact of ST2 genetics on the conferred benefit of anti-ST2. The model includes representation of a wide array of biologic mechanisms and interventions that will provide mechanistic insight and support clinical program design for a wide range of novel therapies during drug development.
- Open Access
- 1 December 2021
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 11 (5) , 616-627
Quantitative systems pharmacology model‐based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3‐kinase inhibitors
Several PI3K inhibitors are in clinical development for the treatment of various forms of cancers, including pan‐PI3K inhibitors targeting all four PI3K isoforms (α, β, γ, and δ), and isoform‐selective inhibitors. Diarrhea and immune‐mediated colitis are among the adverse events observed with PI3K inhibition which limits the maximal tolerated dose. A quantitative systems pharmacology model was developed to investigate PI3K‐inhibitor‐induced colitis. The effects of individual PI3K isoforms on relevant cellular pathways were incorporated into a mechanistic representation of mucosal inflammation. A virtual clinical population captures the observed clinical variability in the onset timing and rates of diarrhea and colitis for seven clinically tested PI3K inhibitors. Model‐based analysis suggests that colitis development is governed by both the inhibition of PI3Kδ, which drives T cell differentiation and proliferation, and PI3Kα, which regulates epithelial barrier integrity. Specifically, when PI3Kα is inhibited below a given threshold, epithelial barrier dysfunction precipitates an exaggerated T effector response due to PI3Kδ‐inhibition, leading to risk of diarrhea and colitis. This synergy explains why the lowest diarrhea and colitis rates are seen with the weakest PI3Kδ inhibition (alpelisib), and higher rates are seen with strong PI3Kδ inhibition if PI3Kα is even mildly inhibited (e.g., idelalisib), whereas strong PI3Kδ inhibition in the absence of PI3Kα inhibition does not result in high colitis rates (umbralisib). Thus, the model‐based analysis suggests that PI3Kα and δ inhibition play unique but synergistic roles in driving colitis. Finally, we explore if and how dose‐regimen might influence colitis rates for molecules that inhibit both PI3Kα and PI3Kδ.
- 1 December 2021
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 11 (5) , 616-627
Open AccessQuantitative systems pharmacology model‐based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3‐kinase inhibitors
Several PI3K inhibitors are in clinical development for the treatment of various forms of cancers, including pan‐PI3K inhibitors targeting all four PI3K isoforms (α, β, γ, and δ), and isoform‐selective inhibitors. Diarrhea and immune‐mediated colitis are among the adverse events observed with PI3K inhibition which limits the maximal tolerated dose. A quantitative systems pharmacology model was developed to investigate PI3K‐inhibitor‐induced colitis. The effects of individual PI3K isoforms on relevant cellular pathways were incorporated into a mechanistic representation of mucosal inflammation. A virtual clinical population captures the observed clinical variability in the onset timing and rates of diarrhea and colitis for seven clinically tested PI3K inhibitors. Model‐based analysis suggests that colitis development is governed by both the inhibition of PI3Kδ, which drives T cell differentiation and proliferation, and PI3Kα, which regulates epithelial barrier integrity. Specifically, when PI3Kα is inhibited below a given threshold, epithelial barrier dysfunction precipitates an exaggerated T effector response due to PI3Kδ‐inhibition, leading to risk of diarrhea and colitis. This synergy explains why the lowest diarrhea and colitis rates are seen with the weakest PI3Kδ inhibition (alpelisib), and higher rates are seen with strong PI3Kδ inhibition if PI3Kα is even mildly inhibited (e.g., idelalisib), whereas strong PI3Kδ inhibition in the absence of PI3Kα inhibition does not result in high colitis rates (umbralisib). Thus, the model‐based analysis suggests that PI3Kα and δ inhibition play unique but synergistic roles in driving colitis. Finally, we explore if and how dose‐regimen might influence colitis rates for molecules that inhibit both PI3Kα and PI3Kδ.
- Open Access
- 28 August 2020
- Published by Springer Nature in npj Systems Biology and Applications
- Vol. 6 (1) , 1-11
Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling
Mosunetuzumab, a T-cell dependent bispecific antibody that binds CD3 and CD20 to drive T-cell mediated B-cell killing, is currently being tested in non-Hodgkin lymphoma. However, potent immune stimulation with T-cell directed therapies poses the risk of cytokine release syndrome, potentially limiting dose and utility. To understand mechanisms behind safety and efficacy and explore safety mitigation strategies, we developed a novel mechanistic model of immune and antitumor responses to the T-cell bispecifics (mosunetuzumab and blinatumomab), including the dynamics of B- and T-lymphocytes in circulation, lymphoid tissues, and tumor. The model was developed and validated using mosunetuzumab nonclinical and blinatumomab clinical data. Simulations delineated mechanisms contributing to observed cell and cytokine (IL6) dynamics and predicted that initial step-fractionated dosing limits systemic T-cell activation and cytokine release without compromising tumor response. These results supported a change to a step-fractionated treatment schedule of mosunetuzumab in the ongoing Phase I clinical trial, enabling safer administration of higher doses.
- 28 August 2020
- Published by Springer Nature in npj Systems Biology and Applications
- Vol. 6 (1) , 1-11
Open AccessMitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling
Mosunetuzumab, a T-cell dependent bispecific antibody that binds CD3 and CD20 to drive T-cell mediated B-cell killing, is currently being tested in non-Hodgkin lymphoma. However, potent immune stimulation with T-cell directed therapies poses the risk of cytokine release syndrome, potentially limiting dose and utility. To understand mechanisms behind safety and efficacy and explore safety mitigation strategies, we developed a novel mechanistic model of immune and antitumor responses to the T-cell bispecifics (mosunetuzumab and blinatumomab), including the dynamics of B- and T-lymphocytes in circulation, lymphoid tissues, and tumor. The model was developed and validated using mosunetuzumab nonclinical and blinatumomab clinical data. Simulations delineated mechanisms contributing to observed cell and cytokine (IL6) dynamics and predicted that initial step-fractionated dosing limits systemic T-cell activation and cytokine release without compromising tumor response. These results supported a change to a step-fractionated treatment schedule of mosunetuzumab in the ongoing Phase I clinical trial, enabling safer administration of higher doses.
- Open Access
- 14 April 2019
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 8 (6) , 340-343
A Flexible Approach for Context‐Dependent Assessment of Quantitative Systems Pharmacology Models
- 14 April 2019
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 8 (6) , 340-343
Open AccessA Flexible Approach for Context‐Dependent Assessment of Quantitative Systems Pharmacology Models
- Open Access
- 4 September 2017
- Published by Springer Nature in npj Systems Biology and Applications
- Vol. 3 (1) , 25
Erratum: Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model
A correction to this article has been published and is linked from the HTML version of this article.
- 4 September 2017
- Published by Springer Nature in npj Systems Biology and Applications
- Vol. 3 (1) , 25
Open AccessErratum: Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model
A correction to this article has been published and is linked from the HTML version of this article.